207 related articles for article (PubMed ID: 26378866)
1. Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review.
van Doorn E; Liu H; Huckriede A; Hak E
Hum Vaccin Immunother; 2016; 12(1):159-69. PubMed ID: 26378866
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults.
Baay M; Bollaerts K; Verstraeten T
Vaccine; 2018 Jul; 36(29):4207-4214. PubMed ID: 29885773
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
Roestenberg M; Remarque E; de Jonge E; Hermsen R; Blythman H; Leroy O; Imoukhuede E; Jepsen S; Ofori-Anyinam O; Faber B; Kocken CH; Arnold M; Walraven V; Teelen K; Roeffen W; de Mast Q; Ballou WR; Cohen J; Dubois MC; Ascarateil S; van der Ven A; Thomas A; Sauerwein R
PLoS One; 2008; 3(12):e3960. PubMed ID: 19093004
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.
Lawrence GW; Saul A; Giddy AJ; Kemp R; Pye D
Vaccine; 1997 Feb; 15(2):176-8. PubMed ID: 9066035
[TBL] [Abstract][Full Text] [Related]
5. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
[TBL] [Abstract][Full Text] [Related]
6. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
[TBL] [Abstract][Full Text] [Related]
7. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
[TBL] [Abstract][Full Text] [Related]
8. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
[TBL] [Abstract][Full Text] [Related]
9. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.
Ren J; Yang L; Xu H; Zhang Y; Wan M; Liu G; Zhao L; Wang L; Yu Y
Vaccine; 2011 Oct; 29(45):7960-5. PubMed ID: 21872635
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.
Durando P; Rosselli R; Cremonesi I; Orsi A; Albanese E; Barberis I; Paganino C; Trucchi C; Martini M; Marensi L; Turello V; Study Group TL; Bregante A; Cacciani R; Iudici R; La Marca D; Pedano L; Petrucci AF; Santolini M; Sbisà V; Zacconi M
Hum Vaccin Immunother; 2015; 11(1):172-7. PubMed ID: 25483531
[TBL] [Abstract][Full Text] [Related]
12. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
Rosenberg SA; Yang JC; Kammula US; Hughes MS; Restifo NP; Schwarz SL; Morton KE; Laurencot CM; Sherry RM
J Immunother; 2010; 33(6):626-9. PubMed ID: 20551834
[TBL] [Abstract][Full Text] [Related]
13. Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection.
Jang SI; Lillehoj HS; Lee SH; Lee KW; Park MS; Bauchan GR; Lillehoj EP; Bertrand F; Dupuis L; Deville S
Vet Parasitol; 2010 Sep; 172(3-4):221-8. PubMed ID: 20541870
[TBL] [Abstract][Full Text] [Related]
14. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.
Bigaeva E; Doorn Ev; Liu H; Hak E
PLoS One; 2016; 11(5):e0154757. PubMed ID: 27149269
[TBL] [Abstract][Full Text] [Related]
16. Montanide ISA 71 VG is Advantageous to Freund's Adjuvant in Immunization Against S. aureus Infection of Mice.
Klimka A; Michels L; Glowalla E; Tosetti B; Krönke M; Krut O
Scand J Immunol; 2015 May; 81(5):291-7. PubMed ID: 25689117
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
[TBL] [Abstract][Full Text] [Related]
18. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.
Toledo H; Baly A; Castro O; Resik S; Laferté J; Rolo F; Navea L; Lobaina L; Cruz O; Míguez J; Serrano T; Sierra B; Pérez L; Ricardo ME; Dubed M; Lubián AL; Blanco M; Millán JC; Ortega A; Iglesias E; Pentón E; Martín Z; Pérez J; Díaz M; Duarte CA
Vaccine; 2001 Jul; 19(30):4328-36. PubMed ID: 11457560
[TBL] [Abstract][Full Text] [Related]
20. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
